BAN2401

Experimental Alzheimer’s Drug Significantly Slowed Patients’ Cognitive Decline

The surprising results have buoyed hopes for treatment

• By Damian Garde, STAT on July 25, 2018

An investigational Alzheimer’s drug significantly slowed patients’ cognitive decline in a large clinical trial, unexpected and unprecedented results that could move the treatment’s makers to roll the dice on an early approval.

In the study, the highest-tested dose of a drug from Biogen and Eisai was markedly better than placebo at delaying the memory-destroying effects of Alzheimer’s. After 18 months, patients who got the drug, called BAN2401, performed 30 percent better on a cognitive test than those getting placebo./.../